DERM Dermira Inc.

8.61
-0.15  -2%
Previous Close 8.76
Open 8.8
Price To Book 6.19
Market Cap 462,079,052
Shares 53,667,718
Volume 634,718
Short Ratio
Av. Daily Volume 713,813

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 5, 2018 - failed to meet all co-primary endpoints.
Olumacostat glasaretil (DRM01)
Acne
Approval announced June 29, 2018.
Glycopyrronium tosylate
Primary axillary hyperhidrosis
Phase 2b data released March 18, 2019 met primary endpoints. Phase 3 trial to be initiated later in 2019.
Lebrikizumab
Atopic Dermatitis
Proof of concept initiation announced February 22, 2019 with data due 2H 2019.
QBREXZA (glycopyrronium)
Primary palmar hyperhidrosis